Florie Borel, Pavlina Konstantinova, Peter L.M. Jansen 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Mestrado Integrado em Medicina Biologia Celular e Molecular II
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
From: Emerging Roles for MicroRNAs in Perioperative Medicine
Biogenesis of micro (mi) and silencing (si)RNAs
Figure Legend: From: Noncoding RNAs:New Players in Chronic Pain
Inflammasomes in liver diseases
M. Louise Hull, Victoria Nisenblat  Reproductive BioMedicine Online 
miRNA genomic organization, biogenesis and function
MicroRNA-mediated DNA methylation in plants
Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer
Volume 152, Issue 5, Pages (April 2017)
M. Louise Hull, Victoria Nisenblat  Reproductive BioMedicine Online 
Andrea L Kasinski, Frank J Slack  Molecular Therapy - Nucleic Acids 
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Volume 64, Issue 6, Pages (June 2016)
Hepatitis C-associated B-cell non-Hodgkin lymphomas
New Hope for a MicroRNA Therapy for Liver Cancer
MicroRNAs: regulators of gene expression and cell differentiation
C. Belair, F. Darfeuille, C. Staedel 
Kai Papenfort, Jörg Vogel  Molecular Cell 
Regulating Cancer Stem Cells the miR Way
Rafael Kramann, Marcus J. Moeller  Kidney International 
Diagnostic Value of Albumin Gene Expression in Liver Tumors: Case Report and Review of the Literature  S. Vincent Rajkumar, M.D., Ronald L. Richardson,
Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma  André Lechel, Michael P. Manns, K.Lenhard Rudolph 
Alterations of the nuclear transport system in hepatocellular carcinoma – New basis for therapeutic strategies  Martin Beck, Peter Schirmacher, Stephan.
MicroRNAs in the Pathogenesis of Lung Cancer
Volume 64, Issue 6, Pages (June 2016)
Exosomes in liver pathology
Volume 84, Issue 6, Pages (December 2013)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Biomarkers of liver cell death
HMGA2, MicroRNAs, and Stem Cell Aging
RNA interference: It's a small RNA world
MicroRNAs: Essential players in the regulation of inflammation
Therapeutic editing of hepatocyte genome in vivo
EASL Clinical Practice Guidelines: Wilson’s disease
miR-34a and the Cardiomyopathy of Senescence: SALT PNUTS, SALT PNUTS!
Marcel Klingenberg, Akiko Matsuda, Sven Diederichs, Tushar Patel 
Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
Volume 116, Issue 2, Pages (January 2004)
MicroRNAs in Liver Disease
Molecular prognostication of liver cancer: End of the beginning
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Gyongyi Szabo, Peter Sarnow, Shashi Bala  Journal of Hepatology 
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
siRNA Versus miRNA as Therapeutics for Gene Silencing
Baekgyu Kim, Kyowon Jeong, V. Narry Kim  Molecular Cell 
MicroRNA Functions in Stress Responses
miR-122 – A key factor and therapeutic target in liver disease
Blinded by the Light: The Growing Complexity of p53
MicroRNAs in cancer: biomarkers, functions and therapy
Molecular Therapy - Nucleic Acids
Volume 60, Issue 5, Pages (May 2014)
Volume 63, Issue 1, Pages (July 2015)
MicroRNA Regulatory Networks in Cardiovascular Development
Volume 65, Issue 4, Pages (October 2016)
Erica E. Marsh, M. D. , Zhihong Lin, Ph. D. , Ping Yin, Ph. D
Long Noncoding RNAs and Hepatocellular Carcinoma
A) Primary microRNA (pri-microRNA) is processed by Drosha in the nucleus to form pre-microRNA. a) Primary microRNA (pri-microRNA) is processed by Drosha.
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Lin28 Mediates the Terminal Uridylation of let-7 Precursor MicroRNA
Markus Bitzer, Iddo Z. Ben-Dov, Thomas Thum  Kidney International 
MicroRNA as Therapeutic Targets for Chronic Wound Healing
Volume 139, Issue 1, Pages (October 2009)
Genetics of hepatocellular carcinoma: The next generation
MicroRNAs in cancer: biomarkers, functions and therapy
Cellular biogenesis of microRNAs.
Small RNAs and Immunity
Presentation transcript:

Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma  Florie Borel, Pavlina Konstantinova, Peter L.M. Jansen  Journal of Hepatology  Volume 56, Issue 6, Pages 1371-1383 (June 2012) DOI: 10.1016/j.jhep.2011.11.026 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 miRNA biogenesis. miRNA biogenesis involves multiple steps requiring (A) RNA Pol II for transcription of the 1–4kb primary transcript called pri-miRNA, (B) nuclease Drosha-DGCR8 for cropping of the single-stranded sequences flanking double-stranded stem–loop structure of the pre-miRNA precursor of ∼70-nt long, (C) export of the pre-miRNA via Exportin-5 from the nucleus to the cytoplasm and (D) nuclease Dicer cleavage of the loop to generate the mature ∼22-nt long miRNA that will be incorporated into the RISC (E). miRNA guide strand is represented in red, and passenger strand is represented in black. Journal of Hepatology 2012 56, 1371-1383DOI: (10.1016/j.jhep.2011.11.026) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 2 miRNAs and their oncogenic and tumor-suppressing targets associated with HCC. Tumor suppressing miRNAs which are downregulated in HCC are indicated in red and oncogenic miRNAs which are upregulated in HCC are indicated in green. miRNAs post-transcriptionally repress the expression of genes involved in cell cycle regulation, (blue); cell proliferation, (grey); apoptosis, (yellow); cell migration and invasion, (white); and of proto-oncogenes, (purple). Genes having a positive effect on the cell process are marked in the dark shade, while genes having a negative effect on the cell process are marked in the light shade. For example, CCND1 is marked in dark blue, because it causes cell cycle progression, and has been linked to the development and progression of cancer. Vice-versa, PTEN is marked in light blue as it causes cell cycle arrest. Additionally, one gene can be targeted by several miRNAs, for example tumor-suppressor PTEN was shown to be simultaneously repressed by oncogenic miR-21 and miR-221. Bar-headed lines indicate post-transcriptional repression of gene expression. Data presented in this figure is non-exhaustive and based on literature. Journal of Hepatology 2012 56, 1371-1383DOI: (10.1016/j.jhep.2011.11.026) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2012 56, 1371-1383DOI: (10. 1016/j. jhep. 2011 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2012 56, 1371-1383DOI: (10. 1016/j. jhep. 2011 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2012 56, 1371-1383DOI: (10. 1016/j. jhep. 2011 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions